Axsome Therapeutics, Inc. (AXSM)

Axsome Therapeutics is transitioning into a leading neuroscience company with three marketed drugs and a robust late-stage pipeline. Q2 2025 saw 72% YoY revenue growth, driven by Auvelity and Sunosi, with improving margins and narrowing net losses. AXSM faces risks from competition, regulatory hurdles, and high valuation, but maintains strong cash reserves and disciplined expense control.

NEW YORK, Oct. 09, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced it is recognizing Mental Illness Awareness Week (MIAW) alongside the national mental health advocacy community including the National Alliance on Mental Illness (NAMI). This year's theme for MIAW is “Building Community: Supporting Mental Well-being Together,” to highlight the importance of meaningful connections, the value of grassroots advocacy, and impact of local action to strengthen mental health support within communities.

NEW YORK, Oct. 07, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced it will report its financial results for the third quarter of 2025 on Monday, November 3, 2025, before the opening of the U.S. financial markets. Axsome management will then host a conference call at 8:00 a.m. Eastern Time to discuss these results and provide a business update.

AXSM's Auvelity drives 82% sales growth in the first half of 2025, with label expansion studies and other marketed products bolstering its CNS drug portfolio.

Every investor wants to outperform the market, but it's a challenging feat to achieve. That's why few manage to do it consistently over long periods.

Axsome Therapeutics, Inc. (NASDAQ:AXSM ) TD Cowen's 5th Annual Novel Mechanisms in Neuropsychiatry & Epilepsy Summit September 17, 2025 8:40 AM EDT Company Participants Mark Jacobson - Chief Operating Officer Nick Pizzie - Chief Financial Officer Conference Call Participants Joseph Thome - TD Cowen, Research Division Presentation Joseph Thome TD Cowen, Research Division Everyone, good morning, and thank you for joining us for our Fifth Annual TD Cowen Novel Mechanisms in Neuropsychiatry and Epilepsy Summit. I'm Joe Thome, one of the senior biotech analysts here on the team at TD Cowen, and it is my pleasure to kick things off this morning with the team from Axsome Therapeutics.

Six poster presentations showcase clinical and real-world data in major depressive disorder, Alzheimer's disease agitation, narcolepsy, and obstructive sleep apnea Six poster presentations showcase clinical and real-world data in major depressive disorder, Alzheimer's disease agitation, narcolepsy, and obstructive sleep apnea

Axsome Therapeutics, Inc. (NASDAQ:AXSM ) Morgan Stanley 23rd Annual Global Healthcare Conference September 8, 2025 2:35 PM EDT Company Participants Mark Jacobson - Chief Operating Officer Nick Pizzie - Chief Financial Officer Conference Call Participants Sean Laaman - Morgan Stanley, Research Division Presentation Sean Laaman Head of Healthcare Research & Equity Analyst Good afternoon, everyone, and welcome to Morgan Stanley Global Healthcare Conference. I'm Sean Laaman, Head of U.S. SMID Cap Biotech Equity Researcher here at the firm.

Axsome (AXSM) reported earnings 30 days ago. What's next for the stock?

AXSM shares rise 20.2% in a month, powered by booming Auvelity sales and a growing CNS drug pipeline.

Axsome Therapeutics, Inc. AXSM reported better-than-expected second-quarter financial results on Monday.

Axsome posts narrower second-quarter loss and 72% revenue surge, driven by strong Auvelity sales.

Axsome Therapeutics, Inc. (NASDAQ:AXSM ) Q2 2025 Earnings Conference Call August 4, 2025 8:00 AM ET Company Participants Ari Maizel - Chief Commercial Officer Darren Opland - Corporate Participant Herriot Tabuteau - Founder, Chairman, CEO & President Nick Pizzie - Chief Financial Officer Conference Call Participants Ashwani Verma - UBS Investment Bank, Research Division Asim Rana - Truist Securities, Inc., Research Division David A. Amsellem - Piper Sandler & Co., Research Division David Timothy Hoang - Deutsche Bank AG, Research Division Graig C.

While the top- and bottom-line numbers for Axsome (AXSM) give a sense of how the business performed in the quarter ended June 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Axsome Therapeutics (AXSM) came out with a quarterly loss of $0.92 per share versus the Zacks Consensus Estimate of a loss of $1. This compares to a loss of $1.24 per share a year ago.